[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527696":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":28,"locations":37,"responsibleParty":55,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"suspected or confirmed myelofibrosis",null,"Patients with suspected or confirmed myelofibrosis;",[13],"Diagnostic Test: 68Ga FAPI PET\u002FCT",{"label":15,"type":10,"description":16,"interventionNames":17},"primary\u002Fsecondary myelofibrosis","Patients with primary\u002Fsecondary myelofibrosis who were not treated with ruxolitinib.",[13],[19],{"type":20,"name":21,"description":21,"armGroupLabels":22,"otherNames":10},"DIAGNOSTIC_TEST","68Ga FAPI PET\u002FCT",[15,9],[24],{"name":25,"affiliation":26,"role":27},"Bing Xu","The First Aiffiliated hosptical of xiamen University","PRINCIPAL_INVESTIGATOR",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+8618750918842","xubingzhangjian@126.com",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Long Liu","+86 151 6000 7832","kucangyaoren@126.com",[38],{"facility":25,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":46,"coordinates":47},"Point",[48,49],118.08187,24.47979,{"lat":49,"lon":48},[52,53],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":34,"role":30,"phone":54,"phoneExt":10,"email":36},"+8615160007832",{"type":27,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Bing, Xu","Principal Investigator","100527696","68ga-fapi-petct-imaging-for-diagnosis-grading-and-efficacy-evaluation-of-myelofibrosis-100527696",false,"NCT06151119","68Ga-FAPI PET\u002FCT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.","A Study to Evaluate 68Ga-FAPI PET\u002FCT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patients with primary\u002Fsecondary myelofibrosis who were not treated with ruxolitinib.\n3. The expected survival time is over 3 months\n4. Voluntarily sign informed consent.\n5. Willing and able to follow the research protocol;\n6. The subject must be able to lie on the scanning bed for 20 minutes;\n\nExclusion Criteria:\n\n1. Known allergic history to 68Ga FAPI or its excipients;\n2. Patients who can not tolerate intravenous drug administration (such as needle fainting and blood fainting history);\n3. Those who are not suitable for or unable to complete imaging tests such as PET due to special reasons, including claustrophobia and radiophobia;\n4. pregnant and lactating women;\n5. Workers who are exposed to radiation for a long period of time;\n6. Serious diseases of the heart, kidney, lung, blood vessel, nervous system, mental system, immune deficiency diseases and hepatitis\u002Fcirrhosis;\n7. Participating in other interventional clinical trials within 1 month before screening;\n8. Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy due to other cancers;\n9. There are other circumstances that the researcher thinks are not suitable for participating in this study;","ALL","18 Years",{"count":68,"type":69},90,"ESTIMATED","OBSERVATIONAL","To evaluate the diagnostic efficacy of 68Ga FAPI PET\u002FCT in myelofibrosis and to identify fibrosis grades.\n\nTo evaluate the diagnostic efficacy of 68Ga FAPIPET\u002FCT imaging in patients with myelofibrosis, compared with conventional CT.",[73],"Primary Myelofibrosis",[75,76],"Myelofibrosis","positron emission tomography \u002F computed tomography","2025-02-18",{"date":79,"type":80},"2025-02-19","ACTUAL",{"date":82,"type":80},"2023-11-22",{"date":84,"type":69},"2027-06-30",{"name":5,"class":6},1]